The ways of reducing diagnostic and therapeutic aggression of the patients with HPV-infection in reproductive age
The problem of early diagnostics and prevention of cervical cancer is actual in Ukraine.The leading etiologic factor in the genesis of cervical neoplasia and a number of other organs is Human papillomavirus (HPV). The human papillomavirus is sexually transmitted and has high contagiosity. Cancer prevention consists in effective screening, early detection and treatment of pathological changes in the cervix. The aggressive treatment of diseases caused by (HPV) has been replaced by a tactic of a differentiated approach, taking into account to the age of the woman and her reproductive plans. The objective: was to study the efficacy and tolerability of the combined use of Proteflazid® systemically in drops form and locally in the form of suppositories for 3 months in patients with cervical intraepithelial neoplasia (CIN) of lung and moderate severity (CIN 1 and CIN 2) associated with the human papillomavirus (HPV); determination on the basis of the results of the need for further destructive treatment. Materials and methods. For the period from July 2016 to September 2017, we examined and treated 86 women with morphologically confirmed intraepithelial neoplasia of the cervix associated with HPV infection. Results. Based on the performed studies, it was found that 6 months after treatment with Proteplasid® systemically and locally for 3 months, regression of CIN was noted in 93% of patients. In all cases, a reduction in viral load of more than 2 Lg of HPV/105, which is a marker of the effectiveness of antiviral therapy, has been recorded. Six months after treatment in 84% of patients and 9 months in 88%, there was complete elimination of HPV or reduced viral load to clinically insignificant values – less than 3 Lg. Conclusion. The drug Proteflazid® suppositories and drops contributes to the elimination of human papillomavirus (HPV) and other viral-bacterial infections and reduces the risk of cervical neoplasia. Key words: cervical cancer, screening, cervical neoplasia, Human papillomavirus, viral-bacterial infections, Proteflazid®.